Reactivation of a latent precore mutant hepatitis B virus related chronic hepatitis during infliximab treatment for severe spondyloarthropathy.
Wendling
D
D
Auge
B
B
Bettinger
D
D
Lohse
A
A
Le Huede
G
G
Bresson-Hadni
S
S
Toussirot
E
E
Miguet
J-P
JP
Herbein
G
G
Di Martino
V
V
D000328:Adult; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D018501:Antirheumatic Agents / Q000009:adverse effects*; D005260:Female; D006515:Hepatitis B virus / Q000187:drug effects / Q000502:physiology*; D006801:Humans; D000069285:Infliximab; D025242:Spondylarthropathies / Q000188:drug therapy*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors; D014775:Virus Activation / Q000187:drug effects*
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab